NO950134L - Formuleringer for oralt administrerte farmasöytiske midler - Google Patents
Formuleringer for oralt administrerte farmasöytiske midlerInfo
- Publication number
- NO950134L NO950134L NO950134A NO950134A NO950134L NO 950134 L NO950134 L NO 950134L NO 950134 A NO950134 A NO 950134A NO 950134 A NO950134 A NO 950134A NO 950134 L NO950134 L NO 950134L
- Authority
- NO
- Norway
- Prior art keywords
- formulations
- orally administered
- pharmaceutical agents
- administered pharmaceutical
- compound
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000021588 free fatty acids Nutrition 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 238000012385 systemic delivery Methods 0.000 abstract 1
- 238000012384 transportation and delivery Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det blir beskrevet nye formuleringer for levering av farmasøytiske forbindelser ved oral administrasjon, som muliggjør betydelig biotllgjengelighet av den aktive Ingrediensen l formuleringen. Disse formuleringene omfatter en farmasøytisk forbindelse som er hoved- sakelig uoppløsellg i vann. Forbindelsen blir oppløst i en bærer som omfatter en langkjedet fri fettsyre som oppløselighetsmlddel, en farmasøytisk akseptabel olje og et overflateaktlvt middel. Ved denne formuleringen blir opplesellgheten av den farmasøytiske forbindelsen øket, og derved blir den systemiske leveringen for- bedret.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20342494A | 1994-03-01 | 1994-03-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO950134D0 NO950134D0 (no) | 1995-01-13 |
NO950134L true NO950134L (no) | 1995-09-04 |
Family
ID=22753951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO950134A NO950134L (no) | 1994-03-01 | 1995-01-13 | Formuleringer for oralt administrerte farmasöytiske midler |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0670166A3 (no) |
JP (1) | JPH0840936A (no) |
KR (1) | KR950031039A (no) |
CN (1) | CN1114588A (no) |
AU (1) | AU1354495A (no) |
BR (1) | BR9500754A (no) |
CA (1) | CA2138607A1 (no) |
CZ (1) | CZ51995A3 (no) |
HU (1) | HUT75252A (no) |
IL (1) | IL112745A0 (no) |
NO (1) | NO950134L (no) |
NZ (1) | NZ270145A (no) |
PE (1) | PE10396A1 (no) |
PL (1) | PL307469A1 (no) |
ZA (1) | ZA95936B (no) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9705813D0 (en) * | 1997-03-20 | 1997-05-07 | Smithkline Beecham Plc | Novel compositions |
JP2002534371A (ja) * | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
KR100435141B1 (ko) * | 2000-12-28 | 2004-06-09 | 한미약품 주식회사 | 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법 |
KR100455216B1 (ko) * | 2001-06-27 | 2004-11-09 | 한미약품 주식회사 | 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법 |
KR100425755B1 (ko) * | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
US20050058670A1 (en) * | 2003-09-09 | 2005-03-17 | Jong-Soo Woo | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
BRPI0917868A2 (pt) | 2008-11-20 | 2016-11-08 | Techno Guard Co Ltd | formulação não emulsão compreendendo derivado de pirazolona e agente solubilizante anfifílico, kit compreendendo a referida formulação e usos |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
EP2480209A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes comprising docetaxel |
WO2018102345A1 (en) * | 2016-11-30 | 2018-06-07 | Agrobiologics Llc | Use of the antifungal aureobasidin a in agriculture |
US20220160731A1 (en) * | 2019-05-20 | 2022-05-26 | Poviva Corp. | Compositions comprising biologically active agents and bile salts |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE445174B (sv) * | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
JPH04305534A (ja) * | 1991-04-02 | 1992-10-28 | Takara Shuzo Co Ltd | オーレオバシジン類製剤 |
GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
JPH0672890A (ja) * | 1992-06-26 | 1994-03-15 | Nippon Kayaku Co Ltd | オーレオバシジン類の乳化製剤 |
-
1994
- 1994-12-15 NZ NZ270145A patent/NZ270145A/en unknown
- 1994-12-20 CA CA002138607A patent/CA2138607A1/en not_active Abandoned
-
1995
- 1995-01-13 NO NO950134A patent/NO950134L/no unknown
- 1995-02-06 ZA ZA95936A patent/ZA95936B/xx unknown
- 1995-02-23 BR BR9500754A patent/BR9500754A/pt not_active Application Discontinuation
- 1995-02-23 EP EP95102558A patent/EP0670166A3/en not_active Withdrawn
- 1995-02-23 IL IL11274595A patent/IL112745A0/xx unknown
- 1995-02-27 PE PE1995262772A patent/PE10396A1/es not_active Application Discontinuation
- 1995-02-27 CZ CZ95519A patent/CZ51995A3/cs unknown
- 1995-02-28 JP JP7039892A patent/JPH0840936A/ja active Pending
- 1995-02-28 HU HU9500618A patent/HUT75252A/hu unknown
- 1995-02-28 KR KR1019950003982A patent/KR950031039A/ko not_active Withdrawn
- 1995-02-28 CN CN95101780A patent/CN1114588A/zh active Pending
- 1995-02-28 PL PL95307469A patent/PL307469A1/xx unknown
- 1995-02-28 AU AU13544/95A patent/AU1354495A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HU9500618D0 (en) | 1995-04-28 |
JPH0840936A (ja) | 1996-02-13 |
KR950031039A (ko) | 1995-12-18 |
EP0670166A2 (en) | 1995-09-06 |
NO950134D0 (no) | 1995-01-13 |
NZ270145A (en) | 1996-08-27 |
IL112745A0 (en) | 1995-05-26 |
AU1354495A (en) | 1995-09-07 |
ZA95936B (en) | 1995-10-09 |
EP0670166A3 (en) | 1996-06-12 |
CA2138607A1 (en) | 1995-09-02 |
BR9500754A (pt) | 1995-10-24 |
PL307469A1 (en) | 1995-09-04 |
CZ51995A3 (en) | 1995-10-18 |
CN1114588A (zh) | 1996-01-10 |
PE10396A1 (es) | 1996-04-11 |
HUT75252A (en) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO950134L (no) | Formuleringer for oralt administrerte farmasöytiske midler | |
CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
ES2110377T1 (es) | Formulacion galenica de fenofibrato y aplicacion de la misma. | |
DK1173153T3 (da) | Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler | |
NO20005431D0 (no) | Gelérbare farmasøytiske preparater | |
AR018829A1 (es) | Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos | |
DK1189620T3 (da) | Formulering indeholdende testosteronundecanoat og amerikansk olie | |
BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
EP0287341B1 (en) | Rectally absorbable form of l-dopa | |
EA200000154A1 (ru) | Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях | |
NO961136L (no) | Farmasöytisk formuleringsgrunnlag for nano-suspensjoner | |
MY100721A (en) | Therapeutic agent. | |
CY1112510T1 (el) | Φαρμακευτικο παρασκευασμα υπο τη μορφη παστας το οποιο περιεχει ενα ασταθες στα οξεα δραστικο συστατικο | |
CO5560580A2 (es) | Formulaciones de sucralosa para disumular sabores desagradables | |
CA2207835A1 (fr) | Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
NO962841D0 (no) | Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler | |
ES2238393T3 (es) | Composiciones farmaceuticas conteniendo mupirocina en forma amorfa. | |
CA2215327A1 (en) | Formulations for lipophilic compounds | |
CA2231342A1 (fr) | Composition pharmaceutique pour administration par voie orale | |
US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
ES2149990T3 (es) | Composiciones farmaceuticas solidas que contienen ingrediente activo de acido (s)-2-(4-isobutilfenil)propionico y celulosa microcristalina y silice coloidal como excipientes. | |
TNSN97134A1 (fr) | Comprime de maleate de trimebutine pellicule | |
AR013967A1 (es) | UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE |